复星医药：控股子公司药品获注册批准

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its sodium phosphonate injection, which is indicated for the treatment of cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus infections in immunocompromised patients [1] Group 1 - The approval of the sodium phosphonate injection will enhance Fosun Pharma's product line [1] - The sales performance of the newly approved drug is subject to various influencing factors, leading to uncertainty [1]